Systemic Vasculitis

2014 ◽  
pp. 271-276
Author(s):  
Paul F. Dellaripa
Keyword(s):  
Treatment Guidelines ◽  
Systemic Vasculitis ◽  
Treatment Options ◽  
Vascular Occlusion ◽  
Immune Dysregulation ◽  
Tissue Necrosis ◽  
Pathogenic Mechanisms ◽  
Immune Mechanisms ◽  
Future Treatment ◽  
Classification And Treatment

The vasculitides are a group of disorders that are characterized by the presence of inflammation in vessel walls, which leads to vascular occlusion and tissue necrosis. Systemic vasculitic syndromes can present clinically in protean fashion and may be due to a variety of mechanisms involving immune dysregulation that leads to endovascular inflammation. However, these immune mechanisms are still not well understood, and thus, one must rely on clinical, descriptive parameters for classification and treatment. This chapter focuses on well-recognized patterns of presentation, treatment guidelines, and emerging insights on pathogenic mechanisms and implications for future treatment options.

scholarly journals Behcet's Disease: New Concepts in Cardiovascular Involvements and Future Direction for Treatment

2012 ◽  
Vol 2012 ◽  
pp. 1-13 ◽  
Author(s):  
M. B. Owlia ◽  
G. Mehrpoor
Keyword(s):  
Behçet’S Disease ◽  
Behcet’S Disease ◽  
Behçet's Disease ◽  
Systemic Vasculitis ◽  
Treatment Options ◽  
Behcet's Disease ◽  
Future Treatment ◽  
New Concepts ◽  
Future Direction

Behcet’s disease (BD) is the only systemic vasculitis involving both arteries and vein in any sizes. It frequently encounters in rheumatology clinics. It has some major morbidities and even fatal outcomes in some cases. The aim of this paper is to analyze the main concepts on pathophysiology and treatment options in BD, focusing on cardiovascular aspects, thrombosis, and potential future treatment.

Long-term survival of the nasal NK/T cell lymphoma

2008 ◽  
Vol 149 (17) ◽  
pp. 801-805
Author(s):  
Péter Rajnics ◽  
László Krenács ◽  
András Kenéz ◽  
Zoltán Járay ◽  
Enikő Bagdi ◽  
...  
Keyword(s):  
T Cell ◽  
Treatment Guidelines ◽  
Cell Lymphoma ◽  
Treatment Options ◽  
Diagnostic Procedures ◽  
T Cell Lymphoma ◽  
Term Survival ◽  
Barr Virus ◽  
Significant Difference ◽  
Nk T Cell

The nasal NK/T cell lymphoma is a rare, extranodal non-Hodgkin lymphoma in western civilizations, which has poor prognosis. The Epstein–Barr virus can be detected in tumor cells in nearly all cases. There are no definite treatment guidelines in our days. There is no significant difference in survival between radiotherapy and chemotherapy according to Asian studies. In this case study we show our diagnostic procedures, our treatment options and we present the summary of this illness based on the data found in the literature.

scholarly journals Personalized treatment options for chronic diseases using precision cohort analytics

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kenney Ng ◽  
Uri Kartoun ◽  
Harry Stavropoulos ◽  
John A. Zambrano ◽  
Paul C. Tang
Keyword(s):  
Decision Making ◽  
Chronic Diseases ◽  
Primary Care Physicians ◽  
Treatment Guidelines ◽  
Point Of Care ◽  
Data Extraction ◽  
Treatment Options ◽  
Personalized Treatment ◽  
Medical Decision ◽  
Similarity Model

AbstractTo support point-of-care decision making by presenting outcomes of past treatment choices for cohorts of similar patients based on observational data from electronic health records (EHRs), a machine-learning precision cohort treatment option (PCTO) workflow consisting of (1) data extraction, (2) similarity model training, (3) precision cohort identification, and (4) treatment options analysis was developed. The similarity model is used to dynamically create a cohort of similar patients, to inform clinical decisions about an individual patient. The workflow was implemented using EHR data from a large health care provider for three different highly prevalent chronic diseases: hypertension (HTN), type 2 diabetes mellitus (T2DM), and hyperlipidemia (HL). A retrospective analysis demonstrated that treatment options with better outcomes were available for a majority of cases (75%, 74%, 85% for HTN, T2DM, HL, respectively). The models for HTN and T2DM were deployed in a pilot study with primary care physicians using it during clinic visits. A novel data-analytic workflow was developed to create patient-similarity models that dynamically generate personalized treatment insights at the point-of-care. By leveraging both knowledge-driven treatment guidelines and data-driven EHR data, physicians can incorporate real-world evidence in their medical decision-making process when considering treatment options for individual patients.

scholarly journals Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus

2021 ◽  
Author(s):  
Hitoshi Sakurai ◽  
Norio Yasui-Furukori ◽  
Takefumi Suzuki ◽  
Hiroyuki Uchida ◽  
Hajime Baba ◽  
...  
Keyword(s):  
Relapse Prevention ◽  
Negative Symptoms ◽  
Japanese Society ◽  
Treatment Guidelines ◽  
Treatment Options ◽  
Standard Deviation Score ◽  
Expert Consensus ◽  
Depression And Anxiety ◽  
First Line ◽  
A Current

Abstract Introduction Conventional treatment guidelines of schizophrenia do not necessarily provide solutions on clinically important issues. Methods A total of 141 certified psychiatrists of the Japanese Society of Clinical Neuropsychopharmacology evaluated treatment options regarding 19 clinically relevant situations in the treatment of schizophrenia with a 9-point scale (1=“disagree” and 9=“agree”). Results First-line antipsychotics varied depending on predominant symptoms: risperidone (mean±standard deviation score, 7.9±1.4), olanzapine (7.5±1.6), and aripiprazole (6.9±1.9) were more likely selected for positive symptoms; aripiprazole (7.6±1.6) for negative symptoms; aripiprazole (7.3±1.9), olanzapine (7.2±1.9), and quetiapine (6.9±1.9) for depression and anxiety; and olanzapine (7.9±1.5) and risperidone (7.5±1.5) for excitement and aggression. While only aripiprazole was categorized as a first-line treatment for relapse prevention (7.6±1.0) in patients without noticeable symptoms, aripiprazole (8.0±1.6) and brexpiprazole (6.9±2.3) were categorized as such for social integration. First-line treatments in patients who are vulnerable to extrapyramidal symptoms include quetiapine (7.5±2.0) and aripiprazole (6.9±2.1). Discussion These clinical recommendations represent the expert consensus on the use of a particular antipsychotic medication for a particular situation, filling a current gap in the literature.

scholarly journals Current and future treatment options in SIADH

2009 ◽  
Vol 2 (suppl 3) ◽  
pp. iii12-iii19 ◽  
Author(s):  
R. Zietse ◽  
N. van der Lubbe ◽  
E. J. Hoorn
Keyword(s):  
Treatment Options ◽  
Future Treatment

An overview of current and future treatment options for adults anaplastic oligodendroglial tumors

2014 ◽  
Vol 2 (8) ◽  
pp. 831-840
Author(s):  
François Ducray ◽  
Caroline Dehais ◽  
Jean-Yves Delattre ◽  
Keyword(s):  
Treatment Options ◽  
Future Treatment ◽  
Oligodendroglial Tumors

scholarly journals GUIDELINES FOR TREATMENT OF DEGENERATIVE LUMBAR SPONDYLOLISTHESIS

2016 ◽  
Vol 15 (3) ◽  
pp. 238-240 ◽  
Author(s):  
CARMEN YOSSALETH BRICEÑO-GONZÁLEZ ◽  
ADRIÁN GARCÍA-SUAREZ ◽  
EULALIO ELIZALDE-MARTÍNEZ ◽  
MARIO ANTONIO DOMÍNGUEZ-DE LA PEÑA ◽  
RUBÉN TORRES-GONZÁLEZ ◽  
...  
Keyword(s):  
Treatment Guidelines ◽  
Treatment Options ◽  
Cross Sectional ◽  
Practice Guide ◽  
Transpedicular Instrumentation ◽  
Clinical Presentations ◽  
Study Results ◽  
Degenerative Lumbar Spondylolisthesis ◽  
Axial Symptoms ◽  
Lumbar Spondylolisthesis

ABSTRACT Objectives: To determine the standard of treatment of degenerative lumbar spondylolisthesis in its different clinical presentations in UMAE Dr. Victorio de la Fuente Narváez. Methods: Six cases found in the literature were presented to 36 experts in spine surgery, along with treatment options, to thereby obtain a standard prescription for the treatment of degenerative lumbar spondylolisthesis. Analytical observational cross-sectional descriptive study. Results: It was found that the treatment of choice in cases of degenerative lumbar spondylolisthesis with axial symptoms is conservative. The surgical treatment of choice for both stable and unstable patients with radiculopathy and/or claudication is decompression + posterolateral graft + transpedicular instrumentation + discectomy (graft). Conclusions: We managed to define the degenerative lumbar spondylolisthesis treatment guidelines in our unit, which can serve as a basis for the development of a clinical practice guide.

scholarly journals Countermeasures to Coronavirus Disease 2019: Are Immunomodulators Rational Treatment Options—A Critical Review of the Evidence

2020 ◽  
Vol 7 (7) ◽  
Author(s):  
Daniel B Chastain ◽  
Tia M Stitt ◽  
Phong T Ly ◽  
Andrés F Henao-Martínez ◽  
Carlos Franco-Paredes ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Distress Syndrome ◽  
Treatment Options ◽  
Immune Dysregulation ◽  
Lung Damage ◽  
Safety And Efficacy ◽  
Rational Treatment ◽  
Immunomodulatory Therapies

Abstract Severe acute respiratory syndrome coronavirus 2 is associated with higher concentrations of proinflammatory cytokines that lead to lung damage, respiratory failure, and resultant increased mortality. Immunomodulatory therapy has the potential to inhibit cytokines and quell the immune dysregulation. Controversial data found improved oxygenation after treatment with tocilizumab, an interleukin-6 inhibitor, sparking a wave of interest and resultant clinical trials evaluating immunomodulatory therapies. The purpose of this article is to assess potential proinflammatory targets and review the safety and efficacy of immunomodulatory therapies in managing patients with acute respiratory distress syndrome associated with coronavirus disease 2019.

Sign in / Sign up

Export Citation Format

Share Document